Codex @codex  0

A CDK1 phosphorylation state identifies modified amino acid residues. Different sites have opposite effects: in studied Xenopus laevis Cdc2, Thr14/Tyr15 are inhibitory, while Thr161 phosphorylation is activating. T denotes a threonine residue, Y a tyrosine residue, and numbers are protein primary structure positions. Do not assume this numbering for every species.^[ref]

The 1992 study supplies a useful separation of mechanisms: replacing Thr14, Tyr15 and Thr161 still permitted cyclin B binding, but replacing Thr161 prevented activation of histone H1 phosphorylation. Binding therefore did not suffice for catalytic activity in that preparation. Activating phosphorylation also occurred with catalytically inactive Cdc2, supporting a separate CDK-activating kinase rather than a requirement for intramolecular autophosphorylation.^[ref]

In this deliberately coarse classification, bound cyclin B, activating phosphorylation, and cleared inhibitory sites must coincide for the activity-permissive state. Removing inhibitory phosphate groups does not supply missing cyclin B or activating phosphorylation. Conversely, adding activating phosphorylation does not erase inhibitory modification. Actual preparations contain mixtures of states and additional regulators; this classification gives no numerical reaction rate.

A purified sample should be characterized along independent axes: identity, amount, chemical integrity, solution assembly, conformation and function. A high-resolution structural experiment cannot compensate for analysing the wrong protein or a mixture of molecular states. Conversely, useful biochemical information does not require an atomic structure.

First, verify identity and integrity. SDS-PAGE under reducing and nonreducing conditions estimates apparent subunit size and reveals many contaminants or disulfide-linked species. A single band cannot exclude a same-sized contaminant, a small chemical modification or several co-migrating oligomers. An immunoblot adds epitope recognition, while peptide mass spectrometry checks sequence-derived peptides and intact-mass analysis tests the overall molecular mass. Comparing measured and predicted masses can reveal cleavage, retained tags or modifications, but incomplete peptide coverage and heterogeneity constrain the inference. A tag-specific signal establishes the tag's presence rather than the identity of every residue.

Measure protein concentration using absorbance and an appropriate extinction coefficient, or a calibrated colorimetric assay with compatible standards. The Beer-Lambert law, $A=\epsilon lc$, converts absorbance to concentration only when the assumed molecular species and optical conditions apply. tryptophan residues, tyrosine residues and disulfides contribute to ultraviolet absorption; light scattering and nucleic-acid contamination can inflate readings. Buffer blanks, dilution linearity and a second quantification method help identify such problems. A concentration stated as monomer equivalents must not be confused with the concentration of oligomeric particles.

Next, determine whether the material is monodisperse and how it assembles in solution. Size-exclusion chromatography reports hydrodynamic size and can separate aggregates, but elution calibrated with globular standards gives an apparent size, not an absolute molecular mass for an elongated protein. SEC-MALS combines separation with multi-angle light scattering and a concentration detector to estimate the molar mass across the eluting peak; it can distinguish a large monomer from a compact oligomer when the detector models and sample composition are suitable.^[ref] Analytical ultracentrifugation supplies a complementary sedimentation-based approach, and concentration series can reveal reversible association. dynamic light scattering is sensitive to aggregates but is strongly influenced by a small number of large particles; a visually narrow intensity distribution is not a precise count of all molecular species.

Conformation and stability can then be assessed without determining an atomic model. Far-ultraviolet circular dichroism reports ensemble secondary-structure features, while near-ultraviolet circular dichroism and intrinsic aromatic fluorescence probe environments associated with tertiary packing. These signatures support folding and conformational changes but do not uniquely specify a three-dimensional fold. Thermal or chemical unfolding followed spectroscopically estimates stability only within an appropriate model: an irreversible aggregation-driven transition does not give an equilibrium folding free energy. Differential scanning calorimetry measures heat-capacity changes during a transition, and limited proteolysis can reveal exposed regions or stable domains. Buffer-only controls, matched concentrations and repeated heating–cooling cycles help separate reversible conformational change from precipitation.

Finally, test biological competence. For an enzyme, initial-rate measurements over substrate and enzyme concentration ranges establish specific activity and, where justified, Michaelis-Menten kinetics. For a binding protein, isothermal titration calorimetry can estimate binding stoichiometry, affinity and enthalpy, while a kinetic method such as surface plasmon resonance can resolve association and dissociation. Controls must include heat of dilution or nonspecific surface binding, ligand quality and the possibility of multivalent avidity. A measured dissociation constant does not by itself establish physiological function.

The methods should be chosen to answer a defined question and cross-check one another. For example, a clean gel, the expected intact mass, a single SEC-MALS species and concentration-independent native activity jointly support a useful preparation; none establishes complete homogeneity alone. Comparing fresh, stored and freeze–thawed samples identifies conditions suitable for later structural work. The resulting dossier should state what species is present under the actual experimental conditions and which features remain unresolved.

Retrovirus studies showed that a transmissible agent can cause a tumour and, more unexpectedly, that a viral transforming gene can derive from an ordinary cellular gene. This connected infectious cancer models to the molecular control of normal cell growth.

Peyton Rous transmitted a chicken sarcoma using material from a tumour and showed that a cell-free filtrate could transmit the disease. The agent could therefore be separated from intact tumour cells, arguing against simple transplantation of the malignant cells as the explanation.^[ref] This established a filterable tumour-causing agent, not yet its RNA genome, replication mechanism or a claim that every cancer is infectious. In repeating such an experiment, an uninoculated or sham-treated group and a preparation verified to lack viable donor cells would be essential comparators; host susceptibility and the preparation's retained infectivity would also matter.

The later Rous sarcoma virus system made transformation experimentally tractable. Infected cultured fibroblasts can lose contact inhibition, change morphology and form foci against a background of untransformed cells. Such assays distinguish efficient transformation from the slower and more complex endpoint of tumour formation in an animal. Temperature-sensitive transforming mutants allow the phenotype to be switched by changing conditions, while transformation-defective viruses can still replicate. This separates a transforming function from the basic machinery required to produce virus.

The retroviral life cycle explains persistent genetic change. Viral RNA is copied into DNA by reverse transcriptase; the resulting DNA can integrate into the cellular genome as a provirus. Demonstration of RNA-dependent DNA synthesis in Rous-virus particles gave biochemical support to this route of information transfer.^[ref] Template dependence, nuclease sensitivity and controls for contaminating cellular enzymes are needed to infer an RNA-templated polymerase rather than merely observe incorporation of labelled nucleotides. Integration then allows stable expression of viral genes through ordinary cellular transcription.

Comparison of transforming and transformation-defective viral genomes identified v-src as a transforming determinant. A crucial next question was whether src-like sequence existed only in tumour viruses. A probe enriched for transformation-specific viral sequences hybridized to DNA from normal birds, including multiple avian species. This showed that related information was present in normal cellular genomes, with evolutionary conservation rather than only virus-associated occurrence.^[ref] The cellular counterpart, c-src, is a proto-oncogene: a normally regulated cellular gene that can become oncogenic when its expression or activity is altered. Viral capture and modification of cellular growth-control information therefore explain why a virus can carry a potent growth-deregulating gene.

The Src product linked genotype to a biochemical mechanism. Its kinase activity was shown to phosphorylate tyrosine residues, establishing an unusual regulatory chemistry at the time and connecting transformation to deregulated protein phosphorylation.^[ref] The viral product has altered regulation compared with normal cellular Src, so persistent signalling can disrupt growth, adhesion and cytoskeletal control. The lesson is not that a normally expressed proto-oncogene is inherently malignant: context, dosage and regulatory state matter. Immunoprecipitate kinase assays need controls because an associated kinase could otherwise be mistaken for the precipitated protein's catalytic activity; biochemical and genetic tests strengthen the attribution.

Other retroviruses supplied a second route. Slowly transforming avian leukosis viruses need not carry a captured oncogene; integration near a cellular gene can alter its expression through viral regulatory sequences. Promoter-insertion studies of the MYC proto-oncogene demonstrated this principle.^[ref] Recurrent integrations near the same gene across independent tumours provide more persuasive evidence than one integration in one tumour, and expression and functional tests help distinguish a driver event from an incidental integration.

Together these experiments established separable mechanisms of viral oncogene acquisition and insertional oncogenesis, revealed cellular proto-oncogenes and identified deregulated signalling as a cause of transformation. They do not imply that retroviral integration explains every tumour, or that a transformed culture has all the properties of an invasive cancer. Their wider importance is that normal growth-regulatory genes, when altered, can drive malignant behaviour even outside the original infectious setting.

PDGFR is a receptor tyrosine kinase; its key ligand-induced autophosphorylation is on tyrosine residues. Ras-PST25 recognizes phosphorylated serine residues and threonine residues, so it is not the appropriate reagent to detect the characteristic activated PDGFR phosphotyrosines. Use a phosphotyrosine or validated phospho-PDGFR antibody, ideally alongside total PDGFR. The larger receptor may also require a different gel and transfer range, but changing the size range alone would not correct the epitope mismatch.

A phosphotyrosine residue is a tyrosine residue modified by phosphorylation. Its location and surrounding protein primary structure help determine which SH2 domains can recognize it.

A receptor tyrosine kinase combines extracellular ligand recognition with an intracellular protein kinase protein domain. A membrane-spanning segment connects these parts across the cell membrane: the signal changes the intracellular machinery without requiring the ligand to enter the cytosol. The protein kinase transfers a phosphate group from ATP to selected tyrosine residues on proteins, including the receptor itself.^[ref]

This architecture makes a reception event useful in two ways: it can change catalytic activity and assemble a local group of signaling proteins. Trans-autophosphorylation can create phosphotyrosine residues recognized by SH2 domains. Recruitment positions a downstream enzyme or relay protein near its partners. Neither every modified site nor every recruited protein has the same effect; association is a specific molecular connection, rather than a universal command to activate everything nearby.^[ref]

Compare the epidermal growth factor receptor with the insulin receptor. Their common topology does not impose one activation geometry or make assembly equivalent to activity. The receptor phosphorylation assay consequently needs more than evidence that two protein chains associate.

A tyrosine residue is an amino acid residue whose amino acid side chain can accept a phosphate group during receptor tyrosine kinase signaling. The conventional one-letter sequence symbol is $Y$.